These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 23807520)

  • 1. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
    Kuhadiya ND; Malik R; Bellini NJ; Patterson JL; Traina A; Makdissi A; Dandona P
    Endocr Pract; 2013; 19(6):963-7. PubMed ID: 23807520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide as additional treatment for type 1 diabetes.
    Varanasi A; Bellini N; Rawal D; Vora M; Makdissi A; Dhindsa S; Chaudhuri A; Dandona P
    Eur J Endocrinol; 2011 Jul; 165(1):77-84. PubMed ID: 21646283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
    Lane W; Weinrib S; Rappaport J; Hale C
    Diabetes Obes Metab; 2014 Sep; 16(9):827-32. PubMed ID: 24589127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
    Varanasi A; Patel P; Makdissi A; Dhindsa S; Chaudhuri A; Dandona P
    Endocr Pract; 2012; 18(2):140-5. PubMed ID: 21856595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
    Kuhadiya ND; Dhindsa S; Ghanim H; Mehta A; Makdissi A; Batra M; Sandhu S; Hejna J; Green K; Bellini N; Yang M; Chaudhuri A; Dandona P
    Diabetes Care; 2016 Jun; 39(6):1027-35. PubMed ID: 27208343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
    Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM
    Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
    Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
    Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide effective in the severely insulin-resistant patient with type 2 diabetes requiring U-500 insulin: a case report.
    Pantalone KM; Faiman C
    Diabetes Technol Ther; 2013 Apr; 15(4):342-3. PubMed ID: 23379638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2018 Jan; 20(1):178-184. PubMed ID: 28722271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S
    Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
    Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
    Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
    Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
    Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
    Kielgast U; Krarup T; Holst JJ; Madsbad S
    Diabetes Care; 2011 Jul; 34(7):1463-8. PubMed ID: 21593296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.